Free Trial

Monopar Therapeutics (MNPR) Short Interest Ratio & Short Volume

→ The only AI company to buy (From Porter & Company) (Ad)
Free MNPR Stock Alerts
$0.60
-0.02 (-2.42%)
(As of 10:52 AM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends

Monopar Therapeutics Short Interest Data

Current Short Interest
79,800 shares
Previous Short Interest
92,300 shares
Change Vs. Previous Month
-13.54%
Dollar Volume Sold Short
$47,728.38
Short Interest Ratio
0.1 Days to Cover
Last Record Date
May 15, 2024
Outstanding Shares
17,480,000 shares
Float Size
8,950,000 shares
Short Percent of Float
0.89%
Today's Trading Volume
20,303 shares
Average Trading Volume
3,303,896 shares
Today's Volume Vs. Average
1%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Monopar Therapeutics ?

Sign up to receive the latest short interest report for Monopar Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

MNPR Short Interest Over Time

MNPR Days to Cover Over Time

MNPR Percentage of Float Shorted Over Time

Monopar Therapeutics Short Interest History

Export to Excel
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
5/15/202479,800 shares $47,728.38 -13.5%0.9%0.1 $0.60
4/30/202492,300 shares $60,927.32 -38.5%1.2%0 $0.66
4/15/2024150,000 shares $114,000.00 -12.0%2.0%0 $0.76
3/31/2024170,500 shares $116,110.50 -25.7%2.3%0 $0.68
3/15/2024229,600 shares $149,469.60 -73.0%3.6%0 $0.65
2/29/2024848,800 shares $704,504.00 +1,251.6%13.3%0.2 $0.83
2/15/202462,800 shares $21,358.28 +192.1%1.0%0 $0.34
1/31/202421,500 shares $7,213.25 -76.6%0.3%0.1 $0.34
1/15/202491,900 shares $39,939.74 -12.8%1.4%0.1 $0.43
12/31/2023105,400 shares $35,857.08 +51.4%1.7%0.1 $0.34
12/15/202369,600 shares $25,661.52 -59.0%1.1%0.1 $0.37
11/30/2023169,900 shares $50,970.00 -9.5%2.8%0.2 $0.30
11/15/2023187,800 shares $62,011.56 +277.9%3.1%0.2 $0.33
10/31/202349,700 shares $22,315.30 +7.8%0.9%0.1 $0.45
10/15/202346,100 shares $21,256.71 +27.0%0.8%0.3 $0.46
9/30/202336,300 shares $22,502.37 -43.9%0.6%0.1 $0.62
9/15/202364,700 shares $39,169.38 -33.0%1.1%0.3 $0.61
8/31/202396,600 shares $62,403.60 -65.8%1.9%0.4 $0.65
8/15/2023282,600 shares $192,168.00 +361.0%5.5%0.6 $0.68
7/31/202361,300 shares $45,423.30 +53.3%1.3%0.1 $0.74
7/15/202340,000 shares $40,000.00 -65.4%0.8%0.1 $1.00
6/30/2023115,600 shares $98,838.00 -58.6%2.4%0.4 $0.86
6/15/2023279,100 shares $235,923.23 +231.1%5.7%1 $0.85
5/31/202384,300 shares $82,445.40 +6.6%1.7%0.3 $0.98
5/15/202379,100 shares $68,026.00 +4.9%1.4%2.6 $0.86
4/30/202375,400 shares $84,832.54 +20.8%1.4%2.3 $1.13
4/15/202362,400 shares $78,761.28 -32.5%1.1%1.7 $1.26
3/31/202392,400 shares $128,445.24 +41.1%1.7%2.5 $1.39
3/15/202365,500 shares $172,265.00 +65.0%1.2%2.9 $2.63
2/28/202339,700 shares $124,261.00 +25.6%0.8%1.4 $3.13
2/15/202331,600 shares $116,920.00 -36.2%0.6%1.2 $3.70
1/31/202349,500 shares $177,210.00 +269.4%0.9%1.3 $3.58
1/15/202313,400 shares $36,602.10 +78.7%0.3%0.4 $2.73
12/30/20227,500 shares $17,775.00 -72.7%0.1%0.2 $2.37
12/15/202227,500 shares $72,875.00 -32.4%0.5%0.9 $2.65
11/30/202240,700 shares $104,599.00 +26.8%0.8%1.6 $2.57
11/15/202232,100 shares $90,201.00 +98.2%0.6%1.3 $2.81
10/31/202216,200 shares $39,852.00 +47.3%0.3%0.7 $2.46
10/15/202211,000 shares $19,800.00 -37.5%0.2%1.1 $1.80
9/30/202217,600 shares $26,752.00 +50.4%0.3%1.7 $1.52
The only AI company to buy (Ad)

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.
9/15/202211,700 shares $19,072.17 +62.5%0.2%1.1 $1.63
8/31/20227,200 shares $12,960.00 +166.7%0.1%0.7 $1.80
8/15/20222,700 shares $4,995.00 -70.0%0.1%0.3 $1.85
7/31/20229,000 shares $17,640.00 +38.5%0.2%0.9 $1.96
7/15/20226,500 shares $14,625.00 -12.2%0.1%0.7 $2.25
6/30/20227,400 shares $17,019.26 +13.9%0.2%0.8 $2.30
6/15/20226,500 shares $13,325.00 -40.9%0.1%0.8 $2.05
5/31/202211,000 shares $23,540.00 +254.8%0.2%1.5 $2.14
5/15/20223,100 shares $6,262.00 -18.4%0.1%0.4 $2.02
4/30/20223,800 shares $8,664.00 +31.0%0.1%0.6 $2.28
4/15/20222,900 shares $7,192.00 -55.4%0.1%0.5 $2.48
3/31/20226,500 shares $16,575.00 +140.7%0.1%0.6 $2.55
3/15/20222,700 shares $7,317.00 -29.0%0.1%0.2 $2.71
2/28/20223,800 shares $11,742.00 -46.5%0.1%0.2 $3.09
2/15/20227,100 shares $20,803.00 -59.9%0.1%0.4 $2.93
1/31/202217,700 shares $52,215.00 -10.2%0.4%0.9 $2.95
1/15/202219,700 shares $58,312.00 -30.4%0.4%0.7 $2.96
12/31/202128,300 shares $90,843.00 -25.7%0.6%1 $3.21
12/15/202138,100 shares $146,685.00 -24.1%0.8%1.5 $3.85
11/30/202150,200 shares $220,880.00 -37.2%1.0%0.7 $4.40
11/15/202179,900 shares $388,314.00 -7.5%1.6%1.1 $4.86
10/29/202186,400 shares $414,720.00 +11.2%1.7%1.2 $4.80
10/15/202177,700 shares $381,507.00 -3.5%1.5%1 $4.91
9/30/202180,500 shares $392,035.00 -17.2%1.6%1.1 $4.87
9/15/202197,200 shares $480,168.00 +85.5%1.9%1.3 $4.94
8/31/202152,400 shares $270,908.00 -16.0%1.0%0.7 $5.17
8/13/202162,400 shares $297,024.00 -1.4%1.2%1.8 $4.76
7/30/202163,300 shares $336,123.00 -8.1%1.3%1.9 $5.31
7/15/202168,900 shares $344,500.00 -0.1%1.4%2.4 $5.00
6/30/202169,000 shares $406,410.00 +1.2%1.6%2.2 $5.89
6/15/202168,200 shares $408,518.00 +1.0%1.5%0.8 $5.99
5/28/202167,500 shares $385,425.00 -2.0%1.5%0.8 $5.71
5/14/202168,900 shares $347,945.00 +16.0%1.6%0.8 $5.05
4/30/202159,400 shares $352,836.00 +50.8%1.3%0.2 $5.94
4/15/202139,400 shares $209,608.00 +52.1%0.9%0.1 $5.32
3/31/202125,900 shares $173,530.00 +18.3%0.7%0.1 $6.70
3/15/202121,900 shares $166,440.00 +14.7%0.6%0.1 $7.60
2/26/202119,100 shares $141,149.00 -31.3%0.6%0.1 $7.39
2/12/202127,800 shares $294,680.00 +17.8%0.8%0.1 $10.60
1/29/202123,600 shares $200,836.00 -1.7%0.7%0.3 $8.51
1/15/202124,000 shares $168,240.00 -43.0%0.7%0.6 $7.01
12/31/202042,100 shares $270,282.00 +13.5%1.3%1.2 $6.42
12/15/202037,100 shares $199,969.00 +17.0%1.1%1.2 $5.39
11/30/202031,700 shares $157,866.00 -23.1%1.0%1.6 $4.98
11/15/202041,200 shares $196,112.00 -2.8%1.5%1.8 $4.76
10/30/202042,400 shares $205,640.00 +19.8%1.6%0.2 $4.85
10/15/202035,400 shares $177,354.00 -22.4%1.4%0.2 $5.01
9/30/202045,600 shares $244,078.56 -13.6%1.7%0.3 $5.35
9/15/202052,800 shares $294,624.00 -7.0%2.0%0.3 $5.58
8/31/202056,800 shares $320,920.00 +143.8%2.2%0.3 $5.65
The only AI company to buy (Ad)

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.
8/14/202023,300 shares $136,072.00 +703.5%0.9%0.1 $5.84
7/31/20202,900 shares $21,286.00 -73.2%0.1%0.2 $7.34
7/15/202010,800 shares $85,752.00 +80.0%0.4%0.9 $7.94
6/30/20206,000 shares $41,400.00 +62.2%0.2%0.5 $6.90
6/15/20203,700 shares $30,414.00 +37.0%0.2%0.4 $8.22
5/29/20202,700 shares $21,303.00 +42.1%0.1%0.5 $7.89
5/15/20201,900 shares $15,010.00 -48.7%0.1%0.3 $7.90
4/30/20203,700 shares $27,232.00 +27.6%0.2%0.4 $7.36
4/15/20202,900 shares $22,243.00 -12.1%0.1%0.3 $7.67
3/31/20203,300 shares $25,707.00 +22.2%0.1%0.2 $7.79
3/13/20202,700 shares $18,387.00 -66.7%0.1%0.4 $6.81
2/28/20208,100 shares $51,759.00 -21.4%0.3%0.1 $6.39
2/14/202010,300 shares $90,022.00 -4.6%0.4%0.1 $8.74
1/31/202010,800 shares $104,328.00 +24.1%0.8%0.1 $9.66
1/15/20208,700 shares $112,491.00 +1.2%0.6%0.1 $12.93
12/31/20198,600 shares $141,900.00 No Change0.4%0.1 $16.50

MNPR Short Interest - Frequently Asked Questions

What is Monopar Therapeutics' current short interest?

Short interest is the volume of Monopar Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 79,800 shares of MNPR short. 0.89% of Monopar Therapeutics' shares are currently sold short. Learn More on Monopar Therapeutics' current short interest.

What is a good short interest percentage for Monopar Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.89% of Monopar Therapeutics' floating shares are currently sold short.

Is Monopar Therapeutics' short interest increasing or decreasing?

Monopar Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 79,800 shares, a decline of 13.5% from the previous total of 92,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Monopar Therapeutics' float size?

Monopar Therapeutics currently has issued a total of 17,480,000 shares. Some of Monopar Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Monopar Therapeutics currently has a public float of 8,950,000 shares.

How does Monopar Therapeutics' short interest compare to its competitors?

0.89% of Monopar Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Monopar Therapeutics: Moleculin Biotech, Inc. (1.53%), Edesa Biotech, Inc. (0.47%), Gain Therapeutics, Inc. (0.60%), NextCure, Inc. (0.43%), Reviva Pharmaceuticals Holdings, Inc. (6.38%), NRx Pharmaceuticals, Inc. (7.00%), HCW Biologics Inc. (0.01%), Immuneering Co. (16.80%), DURECT Co. (3.13%), Lexaria Bioscience Corp. (1.40%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

What does it mean to sell short Monopar Therapeutics stock?

Short selling MNPR is an investing strategy that aims to generate trading profit from Monopar Therapeutics as its price is falling. MNPR shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Monopar Therapeutics?

A short squeeze for Monopar Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MNPR, which in turn drives the price of the stock up even further.

How often is Monopar Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MNPR, twice per month. The most recent reporting period available is May, 15 2024.



More Short Interest Resources from MarketBeat

Related Companies:
Short Interest Tools:
This page (NASDAQ:MNPR) was last updated on 5/30/2024 by MarketBeat.com Staff

From Our Partners
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders
The ONE AI Stock to own now. (It’s not Nvidia.)
Weiss Ratings
Must-See: Elon’s New Invention is Absolutely Insane
InvestorPlace
The 7th Trillion Dollar Company?
The Oxford Club
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Biden Nomination CANCELED?
The Freeport Society
BUY ALERT: Tiny tech play partners with US government
Stansberry Research
Gold Set to EXPLODE!
Gold Safe Exchange